Current and emerging treatment options for myopic choroidal neovascularization

References

• AvilaMPWeiterJJJalkhAETrempeCLPruettRCSchepensCLNatural history of choroidal neovascularization in degenerative myopiaOphthalmology19849112157315816084222
   PubMed Web of Science ®Google Scholar
• LevezielNYuYReynoldsRGenetic factors for choroidal neovascularization associated with high myopiaInvest Ophthalmol Vis Sci2012535004500922678500
   PubMed Web of Science ®Google Scholar
• YoshidaTOhno-MatsuiKYasuzumiKMyopic choroidal neovascularization: a 10-year follow-upOphthalmology200311071297130512867382
   PubMed Web of Science ®Google Scholar
• GrossniklausHEGreenWRChoroidal neovascularizationAm J Ophthalmol200413749650315013874
   PubMed Web of Science ®Google Scholar
• VirgiliGMenchiniFLaser photocoagulation for choroidal neovascularisation in pathologic myopiaCochrane Database Syst Rev20054CD00476516235380
   PubMedGoogle Scholar
• ParodiMBIaconoPPapayannisAShethSBandelloFLaser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopiaArch Ophthalmol201012843744220142520
   PubMed Web of Science ®Google Scholar
• AdelbergDADel PrioreLVKaplanHJSurgery for subfoveal membranes in myopia, angiod streaks, and other disordersRetina1995151982057569346
   PubMed Web of Science ®Google Scholar
• HamelinNGlacet-BernardABrindeauCMimounGCoscasGSoubraneGSurgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removalAm J Ophthalmol2002133453053611931787
   PubMed Web of Science ®Google Scholar
• FujikadoTOhjiMKusakaSVisual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathyAm J Ophthalmol2001131110111011162984
   PubMed Web of Science ®Google Scholar
• YamadaYMiyamuraNSuzumaKKitaokaTLong-term follow-up of full macular translocation for choroidal neovascularizationAm J Ophthalmol2010149345345720035923
   PubMed Web of Science ®Google Scholar
• SakimotoSSakaguchiHOhjiMConsecutive case series with long-term follow-up of full macular translocation for myopic choroidal neovascularisationBr J Ophthalmol20149891221122524692747
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial – VIP report no 1Ophthalmology200110884185211320011
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no 3Ophthalmology200311066767212689884
   PubMed Web of Science ®Google Scholar
• HayashiKOhno-MatsuiKTeramukaiSPhotodynamic therapy with verteporfn for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controlsAm J Ophthalmol2008145351852618207125
   PubMed Web of Science ®Google Scholar
• ChenYSLinJYTsengSYYowSGHsuWJTsaiSCPhotodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow upRetina20072783984517891006
   PubMed Web of Science ®Google Scholar
• HayashiKOhno-MatsuiKShimadaNLong-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopiaAm J Ophthalmol2011151113714720970774
   PubMed Web of Science ®Google Scholar
• CoutinhoAMSilvaRMNunesSGCachuloMLFigueiraJPMurtaJNPhotodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-upRetina20113161089109421358463
   PubMed Web of Science ®Google Scholar
• VaranoMIaconoPGiornoPChiaravallotiAParravanoMPhotodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysisOphthalmologica2014231420421024481122
   PubMed Web of Science ®Google Scholar
• RamrattanRSVan der SchaftTLMooyCMMorphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in ageingInvest Ophthalmol Vis Sci1994356285728648188481
   PubMed Web of Science ®Google Scholar
• PeceAIsolaVVadalàMMatrangaDPhotodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term studyRetina200626774675116963846
   PubMed Web of Science ®Google Scholar
• Ruiz-MorenoJMAmatPMonteroJALugoFPhotodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years’ outcomeBr J Ophthalmol200892679279418523084
   PubMed Web of Science ®Google Scholar
• ChewMCTanCSTreatment options for myopic CNV–is photodynamic therapy still relevant?Indian J Ophthalmol201462783483525116788
   PubMed Web of Science ®Google Scholar
• YamamotoIRogersAHReichelEYatesPADukerJSIntravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBr J Ophthalmol200791215716016870653
   PubMed Web of Science ®Google Scholar
• SakaguchiHIkunoYGomiFIntravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBr J Ophthalmol200791216116516914470
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSTatlipinarSDoDVAndenEVCampochiaroPABevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBr J Ophthalmol200589101368137016170134
   PubMed Web of Science ®Google Scholar
• ManzanoRPPeymanGAKhanPKivilcimMTesting intravitreal toxicity of bevacizumab (Avastin)Retina200626325726116508423
   PubMed Web of Science ®Google Scholar
• SilvaRMyopic Maculopathy: a ReviewOphthalmologica2012228419721322846778
   PubMed Web of Science ®Google Scholar
• WangEChenYIntravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysisRetina20133371375139223514793
   PubMed Web of Science ®Google Scholar
• NishijimaKNgYSZhongLVascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injuryAm J Pathol20071711536717591953
   PubMed Web of Science ®Google Scholar
• YodoiYTsujikawaANakanishiHCentral retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularizationAm J Ophthalmol2009147581682419211092
   PubMed Web of Science ®Google Scholar
• ScupolaATibertiACSassoPMacular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year resultsRetina201030573974720038860
   PubMed Web of Science ®Google Scholar
• BabaTKubota-TaniaiMKitahashiMOkadaKMitamuraYYamamotoSTwo-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisationBr J Ophthalmol201094786487019965833
   PubMed Web of Science ®Google Scholar
• IkunoYNagaiYMatsudaSTwo-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularizationAm J Ophthalmol2010149114014619846061
   PubMed Web of Science ®Google Scholar
• Ruiz-MorenoJMMonteroJAIntravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcomeGraefes Arch Clin Exp Ophthalmol2010248793794120221624
   PubMed Web of Science ®Google Scholar
• VoykovBGeliskenFInhoffenWVoelkerMBartz-SchmidtKUZiemssenFBevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?Graefes Arch Clin Exp Ophthalmol2010248454355020111971
   PubMed Web of Science ®Google Scholar
• NakanishiHTsujikawaAYodoiYPrognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularizationEye201125337538121252956
   PubMed Web of Science ®Google Scholar
• GharbiyaMAllieviFConflittiSIntravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective studyClin Ter20101613879320393686
   PubMed Web of Science ®Google Scholar
• El MatriLKortFChebilABouraouiRMerdassiABouladiMIntravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African populationGraefes Arch Clin Exp Ophthalmol201124991287129321484465
   PubMed Web of Science ®Google Scholar
• Calvo-GonzalezCReche-FrutosJDonateJFernandez-PerezCGarcia-FeijooJIntravitreal ranibizumab for myopic choroidal neo-vascularization: factors predictive of visual outcome and need for retreatmentAm J Ophthalmol2011151352953421236413
   PubMed Web of Science ®Google Scholar
• HayashiKShimadaNMoriyamaMHayashiWTokoroTOhno-MatsuiKTwo-year out-comes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopiaRetina201232468769522173286
   PubMed Web of Science ®Google Scholar
• PeirettiEVinciMFossarelloMIntravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study resultsCan J Ophthalmol2012471283322333848
   PubMed Web of Science ®Google Scholar
• OishiAYamashiroKTsujikawaALong-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularizationGraefes Arch Clin Exp Ophthalmol201325111722527326
   PubMed Web of Science ®Google Scholar
• McBrienNANortonTTPrevention of collagen crosslinking increases form-deprivation myopia in tree shrewExp Eye Res19945944754867859823
   PubMed Web of Science ®Google Scholar
• LiangICChangYYLeeTSLinYRLiuKRTreatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin)Int Ophthalmol201434497197724488041
   PubMed Web of Science ®Google Scholar
• SilvaRMRuiz-MorenoJMNascimentoJShort-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularizationRetina20082881117112318788102
   PubMed Web of Science ®Google Scholar
• LaiTYChanWMLiuDTLamDSIntravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopiaRetina200929675075619357555
   PubMed Web of Science ®Google Scholar
• SilvaRMRuiz-MorenoJMRosaPIntravitreal ranibizumab for myopic choroidal neovascularization: 12-month resultsRetina201030340741220094007
   PubMed Web of Science ®Google Scholar
• VadalàMPeceACipollaSIs ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up studyBr J Ophthalmol201195565766120935305
   PubMed Web of Science ®Google Scholar
• WolfSBalciunieneVJLaganovskaGRADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopiaOphthalmology2014121368269224326106
   PubMed Web of Science ®Google Scholar
• TufailANarendranNPatelPJRanibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR studyOphthalmology20131201944194524001532
   PubMed Web of Science ®Google Scholar
• TufailAPatelPJSivaprasadSRanibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR studyEye20132770971523449508
   PubMed Web of Science ®Google Scholar
• WongTYOhno-MatsuiKLevezielNMyopic choroidal neovascularisation: current concepts and update on clinical managementBr J Ophthalmol201599328929624990871
   PubMed Web of Science ®Google Scholar
• FranqueiraNCachuloMLPiresILong-term follow-up of myopic choroidal neovascularization treated with ranibizumabOphthalmologica20122271394422056757
   PubMed Web of Science ®Google Scholar
• IaconoPParodiMBPapayannisAIntravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularizationRetina20123281539154622922846
   PubMed Web of Science ®Google Scholar
• Ruiz-MorenoJMAriasLMonteroJACarneiroASilvaRIntravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcomeBr J Ophthalmol201397111447145024026146
   PubMed Web of Science ®Google Scholar
• Freitas-da-CostaPPinheiro-CostaJCarvalhoBAnti-VEGF therapy in myopic choroidal neovascularization: long-term resultsOphthalmologica20142321576324852069
   PubMed Web of Science ®Google Scholar
• BennettMDYeeWPegaptanib for myopic choroidal neovascularization in a young patientGraefes Arch Clin Exp Ophthalmol2007245690390517115175
   PubMed Web of Science ®Google Scholar
• RinaldiMChiosiFDell’OmoRIntravitreal pegaptanib sodium (macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional studyRetina201333239740222990315
   PubMed Web of Science ®Google Scholar
• KitagawaTYuzawaMIntravitreal pegaptanib sodium, for myopic choroidal neovascularisation: 1 year results of a prospective pilot studyNihon Ganka Gakkai Zasshi2013117434435023767190
   PubMedGoogle Scholar
• KitagawaTYuzawaMComparison of 1-year treatment outcome of intravitreal pegaptanib sodium versus bevacizumab for myopic choroidal neovascularizationNihon Ganka Gakkai Zasshi2013117972773424261187
   PubMedGoogle Scholar
• FarinhaCLBaltarASNunesSGProgression of myopic maculopathy after treatment of choroidal neovascularizationOphthalmologica201423121122024662778
   PubMed Web of Science ®Google Scholar
• NeelamKCheungCMOhno-MatsuiKLaiTYWongTYChoroidal neovascularization in pathological myopiaProg Retin Eye Res201231549552522569156
   PubMed Web of Science ®Google Scholar
• KaiserPKEmerging therapies for neovascular age-related macular degeneration: drugs in the pipelineOphthalmology20131205S11S1523642781
   PubMed Web of Science ®Google Scholar
• JoussemAMKirchhofBSurgery for age-related macular degeneration. Still an option in the age of pharmacotherapy?Klin Monbl Augenheilkd2014231987488225181504
   PubMed Web of Science ®Google Scholar
• KaiserPKSymonsRCShahSMSirna-027 Study InvestigatorsRNAi-based treatment for neovascular age-related macular degeneration by Sirna-027Am J Ophthalmol20101501333920609706
   PubMed Web of Science ®Google Scholar
• NguyenQDSchacharRANduakaCIMONET Clinical Study GroupEvaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)Ophthalmology201211991867187322683252
   PubMed Web of Science ®Google Scholar
• SabbadiniRASphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degenerationBr J Pharmacol201116261225123821091645
   PubMed Web of Science ®Google Scholar
• Ohr Pharmaceutical IncEfficacy and Safety of Squalamine Lactate Eye Drops in Subjects with Neovascular (Wet) Age-Related Macular Degeneration (AMD)Bethesda, MDNational Library of Medicine (US)
   Google Scholar
• DalalMJacobs-ElNNicholsonBSubconjunctival Palomid 529 in the treatment of neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2013251122705270923689994
   PubMed Web of Science ®Google Scholar
• ZhangMZhangJYanMKH902 Phase 1 Study GroupA phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degenerationOphthalmology2011118467267821146224
   PubMed Web of Science ®Google Scholar
• MaclachlanTKLukasonMCollinsMPreclinical safety evaluation of AAV2-sFLT01 a gene therapy for age-related macular degenerationMol Ther201119232633421119620
   PubMed Web of Science ®Google Scholar
• Molecular PartnersAGA Phase I/II, Open-Label, Non-Controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients with Wet Age Related Macular Degeneration (AMD)Bethesda, MDNational Library of Medicine (US)2010
   Google Scholar
• NovartisNCISafety and Efficacy of Oral PTK787 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE)Bethesda, MDNational Library of Medicine (US)
   Google Scholar
• McLaughlinMMPaglioneMGSlakterJInitial exploration of oral pazopanib in healthy participants and patients with age-related macular degenerationJAMA Ophthalmol2013131121595160124113783
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience20043031818182215031496
   PubMed Web of Science ®Google Scholar
• XuXWengYXuLChenHSustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug deliveryInt J Biol Macromol20136027227623748006
   PubMed Web of Science ®Google Scholar
• HiraniAGroverALeeYWPathakYSutariyaVTriamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degenerationPharm Dev Technol2014261725259682
   PubMed Web of Science ®Google Scholar
• ChenLKimIKLaneAMProton beam irradiation for non-AMD CNV: 2-year results of a randomised clinical trialBr J Ophthalmol20149891212121724820046
   PubMed Web of Science ®Google Scholar
• Casaroli-MaranoRPAlforjaSGiraltJFarahMEEpimacular brachytherapy for wet AMD: current perspectivesClin Ophthalmol20143081661167025210436
   PubMedGoogle Scholar
• JacksonTLChakravarthyUSlakterJSINTREPID Study GroupStereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID studyOphthalmology2015122113814525208859
   PubMed Web of Science ®Google Scholar
• LiYJGohLKhorCCGenome-wide association studies reveal genetic variants in CTNND2 for high myopia in Singapore ChineseOphthalmology2011118236837521095009
   PubMed Web of Science ®Google Scholar
• MiyakeMYamashiroKAkagi-KurashigeYVascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopiaOphthalmology2014121122523323953100
   PubMed Web of Science ®Google Scholar